Sanofi (SNY) Change in Receivables (2013 - 2021)

Sanofi has disclosed Change in Receivables across 4 years of filings, most recently posting -$149.9 million for Q4 2021.

• Change in Receivables for Q4 2021 came in at -$149.9 million, down 2564.53% year-over-year; the trailing twelve-month figure through Dec 2021 was $227.5 million (changed N/A YoY), and the FY2025 annual result was -$1.4 billion, down 4576.3% from the prior year.
• Change in Receivables came in at -$149.9 million for Q4 2021 at Sanofi, down from $6.1 million in the prior quarter.
• In the past five years, Change in Receivables ranged from a high of $6.1 million in Q4 2020 to a low of -$149.9 million in Q4 2021.
• The 3-year median for Change in Receivables is -$33.5 million (2019), against an average of -$59.1 million.
• Across the five-year window, Change in Receivables soared 118.13% in 2020 and slumped 2564.53% in 2021, its largest moves.
• Sanofi's Change in Receivables stood at -$33.5 million in 2019, then jumped by 118.13% to $6.1 million in 2020, then tumbled by 2564.53% to -$149.9 million in 2021.
• The last three Change in Receivables figures came in at -$149.9 million (Q4 2021), $6.1 million (Q4 2020), and -$33.5 million (Q4 2019), per Business Quant data.